19d agoSeeking AlphaBULLISH 67Product/PR
Tempus gets FDA clearance for pulmonary hypertension AI
Tempus AI wins FDA 510(k) clearance for ECG-based pulmonary hypertension detection software, expanding its cardiovascular AI suite.
Archived explainer. For the current picture see today's TEM page.
Why Is TEMPUS AI INC A (TEM) Stock Down Today?
By the Top Tier Newswire AI Desk · August 25, 2026 at 12:04 AM ET · reviewed against 5 wire stories
TEMPUS AI INC A (TEM) is down -8.97% in the latest session. Our newswire has captured 5 stories on TEM across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 69/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why TEM stock is down today
Tempus AI Inc A (TEM) fell 8.97% to $66.17 in the session, marking one of the largest declines in its recent volatile 52-week range of $40.77 to $104.32. The move followed a wave of insider selling and unusual call options activity, despite the company securing FDA clearance for a new AI tool. The stock’s sharp drop occurred amid broader market uncertainty and conflicting retail chatter.
What Happened
Tempus received FDA 510(k) clearance for its ECG-PH software, which is intended to detect signs of pulmonary hypertension from standard ECGs. The product is the third in the company’s AI cardiovascular suite and is designed to assist in early detection. However, the company emphasized that the tool is not a stand-alone diagnostic and must be used in conjunction with other clinical assessments.
Simultaneously, three insiders, CEO Fukushima Ryan, CEO and 10% owner Lefkofsky Eric P, and CEO of Diagnostics Schoenherr Thomas Edward, sold shares on August 18. These sales added to a broader pattern of insider activity in the last 90 days, which included 18 total sell transactions totaling $47.5 million. On the same day as the stock’s decline, a notable options print of $5.4 million in call premiums was reported, suggesting aggressive bullish positioning ahead of the move.
What The Data Shows
The stock’s recent performance has been highly volatile, with 2 fresh 52-week highs and 20 fresh 52-week lows recorded on August 25. The company’s fundamentals remain unprofitable, with a trailing twelve-month EPS of -1.43 and a net margin of -17.8%. Despite a 50.4% revenue increase year to date, the stock’s beta of 3.58 indicates it is highly sensitive to market swings. The recent insider selling and unusual options activity suggest mixed signals for investor confidence.
What To Watch
The stock is not scheduled to report earnings in the near term. Traders and investors should monitor the breadth of coverage and sentiment shifts in the coming days, particularly as the stock continues to trade within a volatile 52-week range.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TEM by the numbers
Last: $66.17Session: -8.97%7 sessions: +31.92%Coverage: 5 stories / 5 sourcesAI sentiment: 69/100 (bullish)Mkt cap: $13.1B52w: $40.77 to $104.32
The headlines behind the move
20d agoMarketChameleonBULLISH 73Product/PR
Tempus Gains FDA Clearance for Third AI Cardiovascular Device, Targeting Early Detection of Pulmonary Hypertension August 24, 2026
Tempus has added a new FDA-cleared AI tool, ECG-PH, to its expanding suite for cardiovascular risk detection. The product is designed to analyze standard ECGs and identify patients potentially at risk for pulmonary hypertension, aiming to simplify and improve early-stage detection for clinicians.
20d agoThe FlyBULLISH 67Product/PR
Tempus AI receives FDA clearance for Tempus ECG-PH
20d agoStockTitanBULLISH 67Product/PR
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
The condition affects roughly 1% of people and typically requires invasive right-heart catheterization; Tempus says the software is not a stand-alone diagnostic.
21d agoYahoo FinanceBULLISH 73M&A
Why Tempus AI Skyrocketed This Week
Tempus AI's latest acquisition is looking like a great move.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TEM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TEM move explainers: 2026-09-02 · 2026-08-31 · 2026-08-25 · 2026-08-24 · 2026-08-21 · 2026-08-20 · 2026-08-19